Abstract: The invention concerns a unit comprising a mould (4) adapted to receive a molten metal alloy and the said metal alloy poured therein. The alloy is TiAl.

Abstract: The invention relates to a method for producing multiple metal turbine engine parts, comprising steps consisting in: a) casting a metal alloy in a mould in order to produce a blank (3); and b) machining the blank in order to produce the parts, characterized in that the blank obtained by casting is a solid polyhedron having first and second sides (30a, 30b) and third and fourth sides (30c, 30d), in which the third and fourth sides extend between the first and second sides, flaring apart from the first side towards the second side, first at a first angle and subsequently at a second larger angle, and said at least one part is machined in the blank.

Abstract: The invention relates to a method for producing multiple metal turbine engine parts, comprising steps consisting in: a) casting a metal alloy in a mould in order to produce a blank (3); and b) machining the blank in order to produce the parts, characterized in that the blank obtained by casting is a solid polyhedron with two generally trapezoidal opposing sides (30a, 30b), and the parts are machined in the blank.

Abstract: To obtain an elastomeric composite crumb having a majority of the particle size distribution greater than 0.33 cm, the crumb is obtained by a process whereby the elastomeric composite comprises less than about 0.5 phr of a salt of a C8 to C20 carboxylic acid, or 10 to 20 phr of a tackifying resin or a combination of both an absence of carboxylic acid and the presence of the tackifying resin. The use of one or both methods permits control of crumb particle size distribution in emulsion or solution processes for producing elastomeric nanocomposites. The elastomeric composite is also disclosed.

Abstract: An elastomeric nanocomposite contains: (a) at least one elastomer comprising units derived from isoolefins having from 4 to 7 carbon atoms; (b) at least 10 phr of a carbon black; and (c) at least 1 phr of a nanoclay; wherein when the nanocomposite is used in an article, the article has a gas permeation coefficient of 80.0 cc*mm/[m2-day] at 40° C. The carbon black may be graphitized to reduce interactions between the carbon black and the nanoclays. The elastomeric nanocomposite may, with or without the use of the graphitized carbon black, may calendared or extruded in such a manner as to orient the nanoclay platelets within the composition such that the oriented nanoclay elastomer nanocomposite has an orientation parameter of greater than 0.15.

Abstract: A nanocomposite is formed from at least one copolymer and at least one nanofiller. The copolymer is formed of units derived from isoolefins having from 4 to 7 carbon atoms and multiolefins. The nanofiller comprising a surfactant wherein the surfactant has the structure of (R1R2R3R4)N+ wherein R1 is benzyl derived unit, which may or may not be substituted, wherein R2 is selected from C1 to C26 alkyls, C2 to C26 alkenes, and C3 to C26 aryls, and wherein R3 and R4 are the same or different and are independently selected from C9 to C26 alkyls, C9 to C26 alkenes, and C9 to C26 aryls.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: A nanocomposite comprising at least one elastomer and at least one nanofiller. The elastomer comprises units derived from isoolefins having from 4 to 7 carbon atoms and at least one multiolefin. The nanofiller comprise a layered filler and an amine modifier wherein the nanofiller is substantially free of any unassociated amines. By eliminating unassociated amines in the nanofiller, prior to contact with the elastomer, the nanocomposite has improved processability characteristics while maintaining desired impermeability characteristics.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: An elastomeric nanocomposite is produced from an isobutylene-based polymer and a layered nanofiller. The process of preparing the nanocomposite includes the steps of a) polymerizing isobutylene monomers and multiolefin monomers to produce an isobutylene-based polymer; b) completing at least one mass transfer dependent stage in the process wherein, after completion of the stage and prior to any recovery of the polymer, the polymer is dissolved in a solvent to create a polymer cement; c) contacting the layered nanofiller and the polymer solvent to obtain the nanocomposite; and d) recovering the nanocomposite. The layered nanofiller may be in a slurry prior to contacting with the polymer cement.

Abstract: An elastomeric nanocomposite contains: (a) at least one elastomer comprising units derived from isoolefins having from 4 to 7 carbon atoms; (b) at least 10 phr of a carbon black; and (c) at least 1 phr of a nanoclay; wherein when the nanocomposite is used in an article, the article has a gas permeation coefficient of 80.0 cc*mm/[m2-day] at 40° C. The carbon black may be graphitized to reduce interactions between the carbon black and the nanoclays. The elastomeric nanocomposite may, with or without the use of the graphitized carbon black, may calendared or extruded in such a manner as to orient the nanoclay platelets within the composition such that the oriented nanoclay elastomer nanocomposite has an orientation parameter of greater than 0.15.

Abstract: An elastomeric nanocomposite is produced from an isobutylene-based polymer and a layered nanofiller. The process of preparing the nanocomposite includes the steps of a) polymerizing isobutylene monomers and multiolefin monomers to produce an isobutylene-based polymer; b) completing at least one mass transfer dependent stage in the process wherein, after completion of the stage and prior to any recovery of the polymer, the polymer is dissolved in a solvent to create a polymer cement; c) contacting the layered nanofiller and the polymer solvent to obtain the nanocomposite; and d) recovering the nanocomposite. The layered nanofiller may be in a slurry prior to contacting with the polymer cement.

Abstract: A nanocomposite comprising at least one elastomer and at least one nanofiller. The elastomer comprises units derived from isoolefins having from 4 to 7 carbon atoms and at least one multiolefin. The nanofiller comprise a layered filler and an amine modifier wherein the nanofiller is substantially free of any unassociated amines. By eliminating unassociated amines in the nanofiller, prior to contact with the elastomer, the nanocomposite has improved processability characteristics while maintaining desired impermeability characteristics.

Abstract: A nanocomposite is formed from at least one copolymer and at least one nanofiller. The copolymer is formed of units derived from isoolefins having from 4 to 7 carbon atoms and multiolefins. The nanofiller comprising a surfactant wherein the surfactant has the structure of (R1R2R3R4)N+ wherein R1 is benzyl derived unit, which may or may not be substituted, wherein R2 is selected from C1 to C26 alkyls, C2 to C26 alkenes, and C3 to C26 aryls, and wherein R3 and R4 are the same or different and are independently selected from C9 to C26 alkyls, C9 to C26 alkenes, and C9 to C26 aryls.

Abstract: A copolymer is formed from an isoolefin having from 4 to 7 carbon atoms and an alkylstyrene. The copolymer has a substantially homogeneous compositional distribution. The copolymer has from about 8 to about 12 wt % of alkylstyrene and at least 85 wt % of isoolefin. The copolymer is preferably halogenated with about 1.1 to about 1.5 wt % of a halogen. The copolymer may in elastomeric nanocomposites. To obtain a good dispersion of the nanoclay in a formulated compound, at least one cure accelerator is selected from the group consisting of mercaptobenzothiazole disulfide, mercaptobenzothiazole, cyclohexyl benzothiazole disulfide, dibutyl thiourea, tetramethylthiuram disulfide, 4-4-dithiodimropholine, zinc dimethyldithiocarbamate, and zinc dibutylphosphorodithiate.

Abstract: A stereo system for a vehicle includes at least one speaker rotatably mounted to an access door of the vehicle between a stowed position and a deployed position. The at least one speaker directs sound to an area within the vehicle in the stowed position and directs sound to an area outside of the vehicle in the deployed position.

Abstract: A cervical isolation and delivery apparatus having a cervical cap removably connected to a syringe such that a bottom opening of the cervical cap is in communication with an internal chamber of the syringe. The syringe is an elongated hollow tube with an elongated rod slidable disposed within an internal chamber of the elongated hollow tube. The cervical cap is removably connected to an application end of the elongated hollow tube such that upon insertion of the apparatus into a patient's vagina, the cervical cap covers the patient's cervix while protecting the tissue surrounding the cervix. The patient's cervix is treated by placing medication, e.g.

Abstract: The invention relates to a new catalyst system that improves the heat transfer capability of a butyl reactor slurry process system in the production of isobutylene-based polymers in continuous slurry polymerization processes. The process is carried out in an anhydrous polymerization system containing a mixture of the monomers in a polar diluent along with a Lewis acid and a C5 or greater initiator having a tertiary halide.

Abstract: The invention provides methods and kits for collection of cervical/vaginal specimen. The specimen is collected for the purpose of detecting the presence or absence of etiological agents, e.g., bacterial or viral agents, including but not limited to human papilloma virus (HPV). The endocervical cells is not required for HPV testing or Pap smear. The methods and kits allow the self-sampling without the aid of trained medical personnel.